Expertise in
5
conditions

Dr. David R. Erb

Pulmonary Medicine | Intensive Care Medicine
151 Harold Fleming Court, 
Spartanburg, SC 
Accepting New Patients
Expertise in
5
conditions
151 Harold Fleming Court, 
Spartanburg, SC 

Overview

David Erb is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Spartanburg, South Carolina. Dr. Erb is highly rated in 5 conditions, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Lung Nodules, Pneumonia, and Advanced Bronchoscopy. Dr. Erb is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pulmonary Medicine
Intensive Care Medicine

Licenses

Critical Care Medicine in SC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

151 Harold Fleming Court, Spartanburg, SC 29303

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Drug, Device
Study Phase: Phase 4
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 7 Less Clinical Trials

1 Total Publications

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
Journal: NPJ primary care respiratory medicine
Published: September 10, 2020
Similar Doctors
Expertise in
17
conditions
Dr. Joseph Boscia
Intensive Care Medicine
Expertise in
17
conditions
Dr. Joseph Boscia
Intensive Care Medicine

Upstate Lung And Critical Care Specialists PC

151 Harold Fleming Ct, 
Spartanburg, SC 
 (0.1 miles away)
864-573-6320
Languages Spoken:
English
See accepted insurances

Joseph Boscia is an Intensive Care Medicine provider in Spartanburg, South Carolina. Dr. Boscia is highly rated in 17 conditions, according to our data. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, Asbestosis, and Advanced Bronchoscopy.

Expertise in
20
conditions
Dr. Rico Vicente
Intensive Care Medicine
Expertise in
20
conditions
Dr. Rico Vicente
Intensive Care Medicine

Raed T Suleiman LLC

2030 N Church Street Pl, 
Spartanburg, SC 
 (1.1 miles away)
864-879-8999
Languages Spoken:
English
See accepted insurances

Rico Vicente is an Intensive Care Medicine provider in Spartanburg, South Carolina. Dr. Vicente is highly rated in 20 conditions, according to our data. His top areas of expertise are Bronchiolitis Obliterans, Industrial Bronchitis, Asthma, Advanced Bronchoscopy, and Gastrostomy.

Expertise in
8
conditions
Dr. Gregory Feldman
Intensive Care Medicine
Expertise in
8
conditions
Dr. Gregory Feldman
Intensive Care Medicine

Upstate Lung And Critical Care Specialists PC

151 Harold Fleming Ct, 
Spartanburg, SC 
 (0.1 miles away)
864-573-6320
Languages Spoken:
English
See accepted insurances

Gregory Feldman is an Intensive Care Medicine provider in Spartanburg, South Carolina. Dr. Feldman is highly rated in 8 conditions, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Bronchiectasis, Advanced Bronchoscopy, and Gastrostomy.

Frequently Asked Questions about Dr. David R. Erb

How do I make an appointment with Dr. David R. Erb?

You can book an appointment with Dr. David R. Erb by calling their office at 864-573-6320. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David R. Erb a top-rated expert for Chronic Obstructive Pulmonary Disease (COPD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David R. Erb is classified as an Distinguished expert for Chronic Obstructive Pulmonary Disease (COPD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David R. Erb specialize in?

While Dr. David R. Erb is a Pulmonary Medicine, they have specific expertise in Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, and Lung Nodules. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. David R. Erb participate in research or clinical trials?

Yes. Dr. David R. Erb has published 1 articles and abstracts on conditions like Chronic Obstructive Pulmonary Disease (COPD). You can view a list of Dr. David R. Erb's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David R. Erb accept my insurance?

Dr. David R. Erb accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 864-573-6320 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Erb's expertise for a condition
ConditionClose
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile